Form 4: Revolution Medicines Director Receives Significant Equity Grant

Revolution Medicines, Inc. Director Sushil Patel reported the acquisition of 3,142 shares of common stock and 11,574 stock options as part of an equity grant on June 26, 2025.

Summary

• Sushil Patel, a Director of Revolution Medicines, Inc. (RVMD), reported changes in beneficial ownership.
• On June 26, 2025, Patel acquired 3,142 shares of common stock at a price of $0.00 per share.
• Following this transaction, Patel beneficially owns a total of 23,090 shares of common stock, which includes 4,017 Restricted Stock Units.
• Additionally, on June 26, 2025, Patel was granted 11,574 stock options with an exercise price of $37.48 per share.
• These options are exercisable as of June 26, 2025, and expire on June 26, 2035.
• The 11,574 shares subject to the option grant will vest in full on the earlier of the first anniversary of June 26, 2025, or immediately prior to the Annual Meeting following the grant date, contingent on Patel remaining a Service Provider.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is generally positive as it aligns interests. No negative or unexpected information is present. The score reflects a neutral to slightly positive event due to insider alignment.

Positives

• Director Sushil Patel received a significant equity grant, aligning his interests with shareholders.
• The grant includes both common stock and stock options, providing a mix of immediate ownership and future upside potential.

Risks

• The vesting of stock options is contingent on the Reporting Person remaining a Service Provider, which is a standard condition for equity grants.

Future Outlook

The vesting schedule for the granted stock options indicates a future milestone for the director's equity ownership, contingent on continued service.

Industry Context

Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, like Revolution Medicines, to align leadership incentives with long-term company performance and shareholder value creation. This practice is common across publicly traded companies, especially those in growth-oriented sectors.

Comparison to Industry Standards

• The grant of equity (common stock and stock options) to a director is a standard compensation practice across industries, particularly in high-growth sectors like biotechnology, to incentivize long-term commitment and performance.
• The exercise price of $37.48 for the stock options is likely based on the market price of RVMD stock on the grant date, which is a common industry standard for option grants.
• The vesting schedule, tied to continued service over one year or until the next annual meeting, is typical for director equity awards, similar to practices at comparable biotech firms such as Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted stock options will vest on the earlier of June 26, 2026 (first anniversary of grant) or immediately prior to the Annual Meeting following the grant date, subject to continued service.

Key Dates

Keywords

Revolution Medicines, RVMD, Sushil Patel, Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership